Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
Clinical trial NCT06599216 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06599216
- Sponsor
- Harbin Medical University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-08
- Primary completion
- 2026-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.